Welcome to our dedicated page for Xenetic Biosciences SEC filings (Ticker: XBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xenetic Biosciences, Inc. (NASDAQ: XBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. According to these filings, Xenetic is a Nevada-incorporated biopharmaceutical company whose common stock trades on The Nasdaq Stock Market under the symbol XBIO, and it focuses on a DNase-based immuno-oncology platform targeting neutrophil extracellular traps (NETs) in difficult to treat cancers.
Through Xenetic’s Form 8-K current reports, investors can review announcements of material events, such as quarterly financial results and the entry into an underwriting agreement for an underwritten public offering of common stock under an effective shelf registration statement on Form S-3. These filings describe, among other things, the number of shares offered, the public offering price, estimated net proceeds and intended uses of proceeds, including working capital, general corporate purposes and advancement of the DNase technology.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to stockholders at the annual meeting, including the election of directors, ratification of the independent registered public accounting firm and an advisory vote on named executive officer compensation. The proxy materials also explain record dates, virtual meeting procedures and how stockholders of record and beneficial owners may vote.
On Stock Titan, these and other SEC documents are updated in near real time from EDGAR. Users can review Xenetic’s 8-Ks for financial result announcements, shelf registration usage and other corporate developments, as well as proxy statements for governance and compensation information. The platform’s AI-powered summaries help interpret complex sections of filings, highlight key terms in offerings and corporate actions, and make it easier to locate information about topics such as capital raises, collaboration agreements and the company’s DNase-based oncology focus without reading every page in full.
Xenetic Biosciences, Inc. filed a prospectus supplement for a public offering that would increase its common stock outstanding beyond the 1,542,139 shares reported as of October 9, 2025. The supplement discloses convertible and exerciseable instruments that could add roughly 0.3 million common-share equivalents: ~0.1M from Series B Preferred conversion, ~0.1M potentially from milestone payments, and ~0.1M from outstanding options, plus 834 shares issuable on warrants.
The filing names Canaccord Genuity LLC as an underwriter and estimates offering expenses payable by the company (excluding underwriting discounts) of approximately $0.2M. It highlights extensive risk factors tied to the DNase technology development, funding needs and potential inability to maintain Nasdaq listing standards, and lists customary securities terms and distribution/resale restrictions across multiple jurisdictions.
Xenetic Biosciences, Inc. reported that it issued a press release with its financial results for the three months ended June 30, 2025. The company furnished this press release as an exhibit to a current report, making the quarter’s performance details available to investors through that document.
The disclosure also includes an extensive caution about forward-looking statements, noting that expectations are subject to numerous risks and uncertainties described in Xenetic’s other SEC reports. The company’s common stock continues to trade on The Nasdaq Stock Market under the symbol XBIO.
Xenetic Biosciences reported a narrowing net loss driven by lower operating expenses while continuing to receive royalties from Takeda. Royalty revenue was $589,897 for the quarter and $1,183,158 for the six months ended June 30, 2025. The company recorded a net loss of $688,703 for the quarter and $1,591,844 for the six-month period. Cash totaled $4,779,846 at June 30, 2025 and working capital was approximately $4.5 million, while total assets were $5.35 million.
Operating costs fell year-over-year as R&D and general and administrative expenses declined, largely reflecting lower personnel and severance-related items recognized in 2024. Management states existing resources are adequate to fund operations for at least twelve months from issuance of these financial statements, but the company anticipates the need for additional capital longer term to advance its DNase clinical program and other initiatives.